Attenuation of Pain in Men and Women

The recruitment status of this study is unknown because the information has not been verified recently.
Verified October 2010 by University of Wisconsin, Madison.
Recruitment status was  Recruiting
Information provided by:
University of Wisconsin, Madison Identifier:
First received: September 28, 2010
Last updated: October 15, 2010
Last verified: October 2010
The purpose of this study is to examine opioid and endocannabinoid mechanisms of exercise-induced analgesia in men and women.

Condition Intervention
Drug: Naltrexone,
Drug: Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Official Title: Attenuation of Pain in Men and Women: Mechanisms of Exercise-Induced Analgesia

Resource links provided by NLM:

Further study details as provided by University of Wisconsin, Madison:

Primary Outcome Measures:
  • Pain threshold, pain ratings, and temporal summation [ Time Frame: Before and immediately following the two experimental sessions ] [ Designated as safety issue: No ]

Estimated Enrollment: 60
Study Start Date: September 2010
Estimated Primary Completion Date: January 2012 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Men Drug: Naltrexone,
50 mg of naltrexone
Drug: Placebo
sugar pill
Active Comparator: Women Drug: Naltrexone,
50 mg of naltrexone
Drug: Placebo
sugar pill


Ages Eligible for Study:   18 Years to 40 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes

Inclusion Criteria: Healthy men and women

Exclusion Criteria:

  • current cardiac or other chronic diseases (e.g., cancer, diabetes, hypertension, kidney disease); routine use of prescriptive medications; history of vasovagal response to phlebotomy; an allergy to naltrexone; pregnancy; current smokers; current use of recreational drugs; history of substance abuse
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01220414

Contact: Kelli F Koltyn, PhD 608-262-4234

United States, Wisconsin
University of Wisconsin-Madison Recruiting
Madison, Wisconsin, United States, 52706
Contact: Kelli F Koltyn, Ph.D.    608-262-4234   
Principal Investigator: Kelli F Koltyn, Ph.D.         
Sponsors and Collaborators
University of Wisconsin, Madison
  More Information

No publications provided

Responsible Party: Kelli F. Koltyn, University of Wisconsin Identifier: NCT01220414     History of Changes
Other Study ID Numbers: H-2010-0087
Study First Received: September 28, 2010
Last Updated: October 15, 2010
Health Authority: United States: Institutional Review Board

Additional relevant MeSH terms:
Central Nervous System Agents
Narcotic Antagonists
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on November 25, 2015